Education
About Us
Working with TipRanks
Follow Us
Omnicell (OMCL)
NASDAQ:OMCL
OMCL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$25.12 - $55.75
Previous CloseN/A
Volume97.52K
Average Volume (3M)608.16K
Market Cap
$1.59B
Enterprise Value$2.07B
Total Cash (Recent Filing)$369.20M
Total Debt (Recent Filing)$371.84M
Price to Earnings (P/E)129.4
Beta0.15
Next Earnings
Apr 24, 2025EPS Estimate
0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.26
Shares Outstanding46,759,415
10 Day Avg. Volume841,784
30 Day Avg. Volume608,165
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.43
Price to Cash Flow (P/CF)7.10
P/FCF Ratio8.40
Enterprise Value/Market Cap1.30
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.39
Enterprise Value/Ebitda44.68
Forecast
1Y Price Target
$49.00Price Target Upside39.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
---
Omnicell News
PremiumCompany Announcements
Omnicell CFO Nchacha Etta Announces Departure
PremiumCompany Announcements
Omnicell Secures CEO Randall Lipps Through 2027
PremiumCompany Announcements
Omnicell’s Earnings Call Highlights Growth Amid Challenges
---
Bulls Say, Bears Say
Bulls Say
GuidanceThe reaffirmed guidance is viewed as a positive.
Market PositionOMCL is a fairly unique HCIT asset, operating in a duopoly and generating a majority of revenue under sole source relationships with over half of the 300 largest U.S. health systems.
Revenue And MarginsNon-GAAP EBITDA was guided above ’25 consensus, underscoring the positive gross margin impact of the new XT products.
Bears Say
Management TransitionThe CFO transition adds incremental execution risk in the near term.
Product Bookings GuidanceOMCL ended the day 11% lower as investors responded to soft 2025 product bookings guidance.
Stock Price ObjectiveThe price objective is lowered to $38 from $46, reflecting incremental execution risk given the management transition and peer group multiple compression.
---
Ownership Overview
2.54% Insiders
30.40% Mutual Funds
17.37% Other Institutional Investors
15.75% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OMCL FAQ
What was Omnicell’s price range in the past 12 months?
Omnicell lowest stock price was $25.12 and its highest was $55.74 in the past 12 months.
What is Omnicell’s market cap?
Omnicell’s market cap is $1.59B.
When is Omnicell’s upcoming earnings report date?
Omnicell’s upcoming earnings report date is Apr 24, 2025 which is in 30 days.
How were Omnicell’s earnings last quarter?
Omnicell released its earnings results on Feb 06, 2025. The company reported $0.6 earnings per share for the quarter, beating the consensus estimate of $0.584 by $0.016.
Is Omnicell overvalued?
According to Wall Street analysts Omnicell’s price is currently Undervalued.
Does Omnicell pay dividends?
Omnicell does not currently pay dividends.
What is Omnicell’s EPS estimate?
Omnicell’s EPS estimate is 0.21.
How many shares outstanding does Omnicell have?
Omnicell has 46,759,415 shares outstanding.
What happened to Omnicell’s price movement after its last earnings report?
Omnicell reported an EPS of $0.6 in its last earnings report, beating expectations of $0.584. Following the earnings report the stock price went down -11.154%.
Which hedge fund is a major shareholder of Omnicell?
Currently, no hedge funds are holding shares in OMCL
---
Omnicell Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$49.00 (39.44% Upside)
$49.00 (39.44% Upside)
Blogger Sentiment
Bullish
OMCL Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 16.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $567.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 8.6%
Last 30 Days ▼ 8.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
19.33%
12-Months-Change
Fundamentals
Return on Equity
1.03%
Trailing 12-Months
Asset Growth
-4.76%
Trailing 12-Months
Company Description
Omnicell
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.
---
OMCL Company Deck
---
OMCL Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong financial performance with revenue growth, profitability, and significant customer wins. However, challenges include a decreased cash balance and flat product bookings outlook for 2025.Read More>---
OMCL Stock 12 Month Forecast
Average Price Target
$49.00
▲(39.44% Upside)
Technical Analysis
Best Analysts Covering OMCL
1 Year
1 Year Success Rate
9/18 ratings generated profit
1 Year Average Return
+7.72%
reiterated a buy rating 2 months ago
Copying Bill Sutherland's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +7.72% per trade.
---